title: The dose of aspirin for the prevention of cardiovascular and cerebrovascular events.
abstract: BACKGROUND
  Low dose aspirin (ASA) (75-325 mg daily) is commonly used for the secondary prevention of cardiovascular and cerebrovascular events, as recommended by US national guidelines. Questions remain, however, as to whether there is a difference in the efficacy and safety across this low dose range.
  
  
  METHODS
  Double-blind controlled studies, meta-analyses, and observational analyses were reviewed to assess the body of evidence regarding the safety and efficacy of aspirin dosing.
  
  
  RESULTS
  Only one double-blind study directly compared two doses of aspirin within the recommended low dose range. No difference in efficacy or safety was observed, although there was a trend toward greater efficacy with ASA 325 mg vs. ASA 81 mg. Three meta-analyses did not find a difference in bleeding events within the low dose range, while one found that higher doses were associated with more events. One meta-analysis found ASA 75-150 mg was as effective as ASA 160-325 mg. Observational analyses of low dose (75-325 mg) ASA from two large controlled trials differed in their results. One study found no difference in the number of cardiovascular/cerebrovascular events, and a significant improvement in mortality with higher doses, while the other found that higher doses were associated with more events.
  
  
  CONCLUSIONS
  There does not appear to be a difference in safety across the low dose range of 75-325 mg based on randomized controlled trial data. Furthermore, ASA 325 mg daily appears to be at least as effective as 75 mg daily. Since the optimal dose of ASA for primary and secondary prevention of events in the broad population is uncertain, dosing considerations should include an evaluation of a patient's individual clinical status as well as an overall cardiovascular and cerebrovascular benefit vs. risk assessment.
authors.affiliation: Medical Affairs, Bayer HealthCare, Morristown, NJ 07962, USA. matt.fisher.b@bayer.com
authors.forename: Matt
authors.initials: M
authors.lastname: Fisher
authors.forename: Volker
authors.initials: V
authors.lastname: Knappertz
mesh_terms: D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002561:Cerebrovascular Disorders / Q000517:prevention & control*; D004311:Double-Blind Method; D006801:Humans; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic
chemical_list: D001241:Aspirin